The second FDA approved CAR T-cell therapy, tisagenlecleucel (KYMRIAHTM) from Novartis pharmaceuticals approved in 2018, is a genetically modified autologous T-cell immunotherapy (CD19 directed) for adult patients with r/r large B-cell lymphoma post two or more lines of systemic therapy, including high-grade B-cell lymphoma DLBCL, and DLBCL arising from follicular lymphoma. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.